Abstract
With regard to the mechanism of selective dopaminergic neuronal death, experimental results of studies on the neurotoxicity of MPTP and rotenone indicate that degeneration of dopamine neurons is closely related to mitochondrial dysfunction, inflammatory process and oxidative stress, particularly with regard to the generation of quinones as dopamine neuron-specific oxidative stress. Thus, it is now clear that the presence of high levels of discompart-mentalized free dopamine in dopaminergic neurons may explain the specific vulnerability of dopaminergic neurons through the generation of highly toxic quinones.
Similar content being viewed by others
References
Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 32:114–118
Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5:165–176
Asanuma M, Miyazaki I, Ogawa N (2004) Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharmac Design 10:695–700
Baez S, Linderson Y, Segura-Aguilar J (1995) Superoxide dismutase and catalase enhance autoxidation during oneelectron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem Mol Med 54:12–18
Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28
Benathan M, Labidi F (1996) Cysteine-dependent 5-S-cysteinyldopa formation and its regulation by glutathione in normal epidermal melanocytes. Arch Dermatol Res 288:697–702
Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J Neurochem 73:1127–1137
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306
Bindoff LA, Birch-Machin M, Cartlidge NEF, Parker JR, Turnbull DM (1989) Mitochondrial function in Parkinson’s disease. Lancet ii:49
Castano A, Herrera AJ, Cano J, Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70:1584–1592
Choi HJ, Kim SW, Lee SY, Hwang Q (2003) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson’s disease. J Neurochem 86:143–152
Chung KK, Dawson VL, Dawson TM (2001) The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci 24:S7–S14
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571–576
Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the a-synuclein protofibril by a dopamine-a-synuclein adduct. Science 294:1346–1349
Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. Faseb J 15:164–170
Dexter DT, Wells FR, Lees AJ, Agid Y, Jenner P, Marsden CD (1989) Increase nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836
Diaz-Corrales FJ, Asanuma M, Miyazaki I, Ogawa N (2004) Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neurosci Lett 354:59–63
Drukarch B, van Muiswinkel FL (2000) Drug treatment of Parkinson’s disease. Time for phase II. Biochem Pharmacol 59:1023–1031
Duffy S, So A, Murphy TH (1998) Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem 71:69–77
Elkon H, Melamed E, Offen D (2001) 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson’s disease. Cell Mol Neurobiol 21:771–781
Foppoli C, Coccia R, Cini C, Rosei MA (1997) Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta 1334:200–206
Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, ASlessandri MG, Paparelli A (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23:8955–8966
Fornstedt B, Rosengren E, Carlsson A (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25:451–454
Gao HM, Hong JS, Zhang W, Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22:782–790
Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 81:1285–1297
Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23:6181–6187
Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci 24:395–401
Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm 50 (Suppl):55–66
Glinka YY, Youdim MB (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292:329–332
Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643
Haque ME, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N (2003) Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 1619:39–52
Hara H, Ohta M, Ohta K, Kuno S, Adachi T (2003) Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Mol Brain Res 119:125–131
Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919–924
Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J Neurochem 86:1297–1307
Hunot S, Brugg B, Ricard D, Michel PP, Muriel M-P, Ruberg M, Faucheux B, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94:7531–7536
Hunot S, Hartmann A, Hirsch EC (2001) The inflammatory response in the Parkinson brain. Clin Neurosci Res 1:434–443
Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 53:S49–S58; discussion S58–S60
Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51–59
Inazu M, Kubota N, Takeda H, Zhang J, Kiuchi Y, Oguchi K, Matsumiya T (1999) Pharmacological characterization of dopamine transport in cultured rat astrocytes. Life Sci 64:2239–2245
Inazu M, Takeda H, Ikoshi H, Uchida Y, Kubota N, Kiuchi Y, Oguchi K, Matsumiya T (1999) Regulation of dopamine uptake by basic fibroblast growth factor and epidermal growth factor in cultured rat astrocytes. Neurosci Res 34:235–244
Ito S, Fujita K (1982) Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. Biochem Pharmacol 31:2887–2889
Jara JR, Aroca P, Solano F, Martinez JH, Lozano JA (1988) The role of sulfhydryl compounds in mammalian melanogenesis: the effect of cysteine and glutathione upon tyrosinase and the intermediates of the pathway. Biochim Biophys Acta 967:296–303
Juorio AV, Li XM, Walz W, Paterson IA (1993) Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res 626:306–309
Keller JN, Huang FF, Dimayuga ER, Maragos WF (2000) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 29:1037–1042
Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease. Neurosci Lett 58:343–346
Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16:724–739
Korytowski W, Sarna T, Kalyanaraman B, Sealy RC (1987) Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta 924:383–392
Kuhn DM, Arthur RE, Jr., Thomas DM, Elferink LA (1999) Tyrosine hydroxylase is inactivated by catecholquinones and converted to a redoxcycling quinoprotein: possible relevance to Parkinson’s disease. J Neurochem 73:1309–1317
Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50–61
Lai CT, Yu PH (1997) Dopamine- and L-b-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 53:363–372
Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46:598–605
LaVoie MJ, Hastings TG (1999) Peroxynitrite-and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem 73:2546–2554
Le WD, Jankovic J, Xie W, Appel SH (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107:1165–1173
Li XM, Juorio AV, Paterson IA, Walz W, Zhu MY, Boulton AA, Inazu M, Takeda H, Matsumiya T (1992) Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells. J Neurochem 59:1172–1175
Lizasoain I, Moro MA, Knowles RG, Darley UV, Moncada S (1996) Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem J 314:877–880
Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson’s disease. J Neurochem 64:1645–1654
McGeer PL, Itagaki S, Boyes B, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46
McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett 326:155–158
McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13:1437–1441
McNaught KS, Jenner P (2001) Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 297:191–194
McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301–306
McNaught KS, Olanow CW (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol 53:S73–S84; discussion S84–S76
McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2:589–594
Meyer M, Schreck R, Baeuerle PA (1993) H2O2 and antioxidants have opposite effects on activation of NF-kB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 12:2005–2015
Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455
Mizuno Y, Sone N, Saitoh T (1987) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylptridinium ion on activities of the enzymes in the electron transport in mouse brain. J Neurochem 48:1787–1793
Munday R, Smith BL, Munday CM (1998) Effects of butylated hydroxyanisole and dicoumarol on the toxicity of menadione to rats. Chem Biol Interact 108:155–170
Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrwhydropyridine-induced neurotoxicity in mice. FASEB J 12:905–912
Nagatsu T (2002) Parkinson’s disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 109:731–745
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm 58(Suppl):277–290
O’Neill LAJ, Kaltschmidt C (1997) NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20:252–258
Offen D, Ziv I, Sternin H, Melamed E, Hochman A (1996) Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson’s disease. Exp Neurol 141:32–39
Pardo B, Mena MA, Casarejos MJ, Paino CL, De Yebenes JG (1995) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res 682:133–143
Paris I, Dagnino-Subiabre A, Marcelain K, Bennett LB, Caviedes P, Caviedes R, Azar CO, Segura-Aguilar J (2001) Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J Neurochem 77:519–529
Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67:269–274
Ramsay RR, Singer TP (1986) Energy dependent uptake of MPP+, the neurotoxic metabolite of MPTP, by mitochondria. J Biol Chem 261:7585–7587
Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Kellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520
Rosei MA, Blarzino C, Foppoli C, Mosca L, Coccia R (1994) Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun 200:344–350
Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA (2002) Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. J Neurosci 22:10690–10698
Sakka N, Sawada H, Izumi Y,Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A (2003) Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport 14:2425–2428
Sampaio-Maia B, Serrao MP, Soaresda-Silva P (2001) Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am J Physiol Cell Physiol 280:C333–C342
Sawada H, Kohno R,Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, Shimohama S (2004) Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279:10710–10719
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–827
Segura-Aguilar J, Baez S, Widersten M, Welch CJ, Mannervik B (1997) Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J Biol Chem 272:5727–5731
Segura-Aguilar J, Metodiewa D, Welch CJ (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381:1–6
Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341:87–90
Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006–7015
Simpson CS, Morris BJ (1999) Activation of nuclear factor kB by nitric oxide in rat striatal neurones: differential inhibition of the p50 and p65 subunits by dexamethasone. J Neurochem 73:353–361
Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112–2122
Stern EL, Quan N, Proescholdt MG, Herkenham M (2000) Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide. J Neuroimmunol 109:245–260
Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97:11869–11874
Sulzer D, Zecca L (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1:181–195
Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N (2001) Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 26:31–36
The Parkinson SG (1989) Effects of deprenyl on progression of disability in early Parkinson’s disease. N Engl J Med 321:1364–1371
Tsai MJ, Lee EH (1996) Characterization of L-DOPA transport in cultured rat and mouse astrocytes. J Neurosci Res 43:490–495
Tse DC, McCreery RL, Adams RN (1976) Potential oxidative pathways of brain catecholamines. J Med Chem 19:37–40
Xu Y, Stokes AH, Roskoski R Jr, Vrana KE (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54:691–697
Yoshioka M, Tanaka K, Miyazaki I, Fujita N, Higashi Y, Asanuma M, Ogawa N (2002) The dopamine agonist cabergoline provides neuroprotection by activation of the glutashione system and scavenging free radicals. Neurosci Res 43:256–267
Zoratti M, Szabo I (1995) The mitochondrial permeability transition. Biochim Biophys Acta 1241:139–176
Ogawa N, Asanuma M, Miyoshi K (2004) Mechanism of specific dopaminergic neuronal death in Parkinson’s disease. Nippon Rinsho 62:1629–1634 (in Japanese with English abstract)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogawa, N., Asanuma, M., Miyazaki, I. et al. L-DOPA treatment from the viewpoint of neuroprotection. J Neurol 252 (Suppl 4), iv23–iv31 (2005). https://doi.org/10.1007/s00415-005-4006-7
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-4006-7